Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial

• Ting Li,
• Fangfang Sun,
• Xiaodong Wang,
• Shuang Ye,
• Sheng Chen,
• Jie Chen,
• Weiguo Wan,
• Sheng-Ming Dai,
• Wenyan Huang,
• Liling Zhao,
• Danting Zhang

Affiliations

Ting Li

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Fangfang Sun

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Xiaodong Wang

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Shuang Ye

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Sheng Chen

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Jie Chen

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Weiguo Wan

Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China

Sheng-Ming Dai

Department of Rheumatology and Immunology, Shanghai Jiao Tong University Affiliated Sixth People`s Hospital, Shanghai, China

Wenyan Huang

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Liling Zhao

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Danting Zhang

Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China